In addition, another study also indicated that METTL3 expression is positively associated with higher malignant grades and poorer prognoses in isocitrate dehydrogenase-wildtype gliomas but not isocitrate dehydrogenase-mutant gliomas, which further suggests that METTL3 can promote the malignant progression of gliomas [61]. This evidence concerns the gene METTL3 and central nervous system cancer.